The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Clinical Evaluation of Once-Weekly Dosing of Epoetin Alfa in Chemotherapy Patients: Improvements in Hemoglobin and Quality of Life Are Similar to Three-Times-Weekly Dosing
Abstract
PURPOSE: To prospectively evaluate the effectiveness, safety, and clinical benefits of once-weekly epoetin alfa therapy as an adjunct to chemotherapy in anemic cancer patients. PATIENTS AND METHODS: A total of 3,012 patients with nonmyeloid malignancies who received chemotherapy were enrolled onto this multicenter, open-label, nonrandomized study conducted in 600 United States community-based practices. Patients received epoetin alfa 40,000 U once weekly, which could be increased to 60,000 U once weekly after 4 weeks dependent on hemoglobin response. Treatment was continued for a maximum of 16 weeks. RESULTS: Among the 2,964 patients assessable for efficacy, epoetin alfa therapy resulted in significant increases in hemoglobin levels, decreases in transfusion requirements, and improvements in functional status and fatigue as assessed by the linear analog scale assessment (energy level, ability to perform daily activities, and overall quality of life) and the anemia subscale of the Functional Assessment of Cancer Therapy–Anemia questionnaire. Improvements in quality-of-life parameters correlated significantly (P < .001) with increased hemoglobin levels. The direct relationship between hemoglobin and quality-of-life improvement was sustained during the 16-week study period, which is similar to findings of large community-based trials of three-times-weekly dosing. Once-weekly epoetin alfa was well tolerated, with most adverse events attributed to the underlying disease or concomitant chemotherapy. CONCLUSION: The results from this large, prospective, community-based trial suggest that once-weekly epoetin alfa therapy increases hemoglobin levels, decreases transfusion requirements, and improves quality of life in patients with cancer and anemia who undergo concomitant chemotherapy. Based on the results of this study, the clinical benefits and the adverse event profile of once-weekly epoetin alfa therapy in community-based practice are similar to those observed in the historical experience with the three-times-weekly dosage schedule.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Clinical applications of visual analogue scales: a critical review
McCormack, H. M., de L. Horne, D. J., & Sheather, S. (1988) · Psychological Medicine · doi:10.1017/s0033291700009934 · Cited by 2,108
Yellen, S. B., Cella, D. F., Webster, K., Blendowski, C., & Kaplan, E. (1997) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(96)00274-6 · Cited by 1,964
Demetri, G. D., Kris, M., Wade, J., Degos, L., & Cella, D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3412 · Cited by 751
Glaspy, J., Bukowski, R., Steinberg, D., Taylor, C., Tchekmedyian, S., & Vadhan-Raj, S. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.1218 · Cited by 693
Cella, D. F. (1997) · PubMed · Cited by 687
Interpretation of quality of life changes
Lydick, E., & Epstein, R. S. (1993) · Quality of Life Research · doi:10.1007/bf00435226 · Cited by 527
Erythropoietin for anaemia in cancer patients
Abels, R. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80281-3 · Cited by 185
Assessment of the quality of life of patients with advanced cancer
Gough, I. R., Furnival, C. M., Schilder, L., & Grove, W. (1983) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(83)90042-1 · Cited by 178
Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin
Leitgeb, C., Pecherstorfer, M., Fritz, E., & Ludwig, H. (1994) · Cancer · doi:10.1002/1097-0142(19940515)73:10<2535::aid-cncr2820731014>3.0.co;2-5 · Cited by 167
Cheung, W. K., Goon, B. L., Guilfoyle, M. C., & Wacholtz, M. C. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90072-8 · Cited by 112
Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients.
Platanias, L. C., Miller, C. B., Mick, R., Hart, R. D., Ozer, H., McEvilly, J. M., Jones, R. J., & Ratain, M. J. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.11.2021 · Cited by 112
Rutherford, C. J., Schneider, T. J., Dempsey, H., Kirn, D. H., Brugnara, C., & Goldberg, M. A. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90134-1 · Cited by 80
Walsh (1995) · doi:10.1002/1097-0142(19951201)76:11
Cited by
Littlewood, T. J., Bajetta, E., Nortier, J. W. R., Vercammen, E., Rapoport, B., & for the Epoetin Alfa Study Group (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.11.2865 · Cited by 974
Ludwig, H., Van Belle, S., Barrett-Lee, P., Birgegård, G., Bokemeyer, C., Gascón, P., Kosmidis, P., Krzakowski, M., Nortier, J., Olmi, P., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.06.019 · Cited by 925
Cella, D., Eton, D. T., Lai, J.-S., Peterman, A. H., & Merkel, D. E. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00529-8 · Cited by 808
Cancer‐related fatigue: Evolving concepts in evaluation and treatment
Stasi, R., Abriani, L., Beccaglia, P., Terzoli, E., & Amadori, S. (2003) · Cancer · doi:10.1002/cncr.11742 · Cited by 712
Erythropoietin: Physiology and Pharmacology Update
Fisher, J. W. (2003) · Experimental Biology and Medicine · doi:10.1177/153537020322800101 · Cited by 708
Metadata
- Authors
- Gabrilove, J. L., Cleeland, C. S., Livingston, R. B., Sarokhan, B., Winer, E., & Einhorn, L. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-06-01
- Volume
- 19
- Issue
- 11
- Pages
- 2875-2882
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1867073577
- Cited by
- 595
- References
- 14
- FWCI
- 34.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.